Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Gains from Investment Securities: 2020-2024

Historic Gains from Investment Securities for GeneDx Holdings (WGS) over the last 5 years, with Dec 2024 value amounting to $13.4 million.

  • GeneDx Holdings' Gains from Investment Securities rose 31.59% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year decrease of 66.55%. This contributed to the annual value of $13.4 million for FY2024, which is 271.60% up from last year.
  • As of FY2024, GeneDx Holdings' Gains from Investment Securities stood at $13.4 million, which was up 271.60% from $3.6 million recorded in FY2023.
  • In the past 5 years, GeneDx Holdings' Gains from Investment Securities registered a high of $13.4 million during FY2024, and its lowest value of -$198.4 million during FY2021.
  • Its 3-year average for Gains from Investment Securities is -$17.8 million, with a median of $3.6 million in 2023.
  • Per our database at Business Quant, GeneDx Holdings' Gains from Investment Securities crashed by 5,047.66% in 2021 and then skyrocketed by 271.60% in 2024.
  • GeneDx Holdings' Gains from Investment Securities (Yearly) stood at $4.0 million in 2020, then slumped by 5,047.66% to -$198.4 million in 2021, then surged by 64.60% to -$70.2 million in 2022, then spiked by 105.12% to $3.6 million in 2023, then soared by 271.60% to $13.4 million in 2024.